论文部分内容阅读
Objective: To study the effect of glycine site/NMDA (N-methyl-D-aspartate) receptor antagonist MRZ2/576 on the conditioned place preference (CPP) and locomotor activity induced by morphine in mice. Methods: Different doses (1.25, 2.5 and 5 mg/kg, i.p.) of MRZ2/576 were used to evaluate the effect of MRZ2/576 on the acquisition and expression of CPP induced by morphine (5 mg/kg) in mice. In addition, we examined the locomotor activity of mice in conditioning and testing phase of CPP paradigm. Results: MRZ2/576 alone could not establish place preference, but a 5 mg/kg dose of MRZ2/576 could block both acquisition and expression of morphine-induced CPP. In testing phase of CPP, there was no statistical difference for locomotor activity between the groups; injection of MRZ2/576 showed a dose-dependent decrease of locomotor activity on both control and morphine-treated mice, especially 5 mg/kg of MRZ2/576 significantly suppressed the locomotor activity of mice. Conclusion: Based on the present results, we assume that MRZ2/576 can antagonize the rewarding effect of morphine, suggesting that this glycine site/NMDA receptor antagonist could be used to treat addictions due to its light side effect profile.
Objective: To study the effect of glycine site / NMDA (N-methyl-D-aspartate) receptor antagonist MRZ2 / 576 on the conditioned place preference (CPP) and locomotor activity induced by morphine in mice. Methods: Different doses and 5 mg / kg, ip) of MRZ2 / 576 were used to evaluate the effect of MRZ2 / 576 on the acquisition and expression of CPP induced by morphine (5 mg / kg) in mice. mice in conditioning and testing phase of CPP paradigm. Results: MRZ2 / 576 alone could not establish place preference, but a 5 mg / kg dose of MRZ2 / 576 could block both acquisition and expression of morphine-induced CPP. In testing phase of CPP , there was no statistical difference for locomotor activity between the groups; injection of MRZ2 / 576 showed a dose-dependent decrease of locomotor activity on both control and morphine-treated mice, especially 5 mg / kg of MRZ2 / 576 significantly suppressed the locomotor activity of mice. Conclusion: Based on the pres ent results, we assume that MRZ2 / 576 can antagonize the rewarding effect of morphine, suggesting that this glycine site / NMDA receptor antagonist could be used to treat addictions due to its light side effect profile.